
News|Articles|January 1, 2012
FDA Pipeline Preview, January 2012 (Alexza Pharmaceuticals, Pfizer, Celladon, Vertex, Avedro)
Recent FDA action (through December 2011) related to staccato loxapine, axitinib, mydicar, kalydeco, riboflavin ophthalmic solution, minocycline hydrochloride
Advertisement
Recommendations for approval
Fast-track designation
Priority review
• First-time generic approval
MInocycline hydrocholride extended-release tablets in 45-mg, 55-mg, 90-mg, and 135-mg strengths (equiv to Solodyn)
LUPIN PHARMACEUTICALS
Newsletter
Get the latest industry news, event updates, and more from Managed healthcare Executive.
Advertisement
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
HS patients on biosimilar adalimumab lose response faster than those on the original drug
2
Global MS analysis links disability burden to rising economic strain
3
CMS negotiates a 70% discount for Ozempic and Wegovy
4
Virtual care replaces, not adds, Medicare visits for health systems, analysis shows
5






















































